Slide 1: First Quarter 2024 Earnings
„ First Quarter 2024 Earnings May 08, 2024
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a
Slide 3: Q1 2024 Results vs PYQ1
Q1 2024 Results vs PYQ1 (in millions) Q1 GAAP Q1 Non-GAAP INSTRUMENTS C O N S U M AB L E S AC C E L E R AT O R OTHER 2023 2024 2023 2024 Revenue Mix 8% 53% 27% 12% Revenue 28.5 32.1 28.5 32.1 Gross Margin $ 16.9 19.6 15.1 17.5 Gross Margin % 59.5% 61.2% 53.1% 54.5% Revenue Q1 2023 Q1 2024 22% Operat
Slide 4: Q1 2024 Cash Balance and Cash Usage
Q1 2024 Cash Balance and Cash Usage (in millions) Liquidity1 • Strong balance sheet, well positioned to fund strategic objectives $305M • Q1 seasonality – highest cash usage quarter Cash • Q1 2024 cash outflow: Outflow • Working Capital: ($16M) • $7M Prior year bonus payout • $4M Receivables - sales
Slide 5: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others PUBLICATIONS BIOM ARKERS INSTRUM ENTS Placements Cumulative Cumulative # of units placed Cumulative 213 Number of Drug 205 2,929 559 561 988 Trial Projects 972 2,781 538 168 27.8 876 480 149 132 23.7 2,
Slide 6: Brain-Derived Tau (BD-Tau)
Brain-Derived Tau (BD-Tau) BD-Tau is derived BD-Tau may also from the brain and may improve the current ATN provide added sensitivity framework for the to a stand-alone definition and staging of P-tau217 test1 Alzheimer’s disease1 Blood-based total tau primarily originates from peripheral sources (e
Slide 7: Early detection of Alzheimer's pathology requires greater sensitivity
Early detection of Alzheimer’s pathology SYMPTOMAT IC requires greater sensitivity 2 30% of symptomatic patients(a) have pathologies other than Addressable by Alzheimer’s and would benefit with AD from differential diagnosis with a 7M in US multi-marker test LIMIT O F DE T E CT IO N O F O T H E R I
Slide 8: Reconciliation of GAAP to Non-GAAP Financial Measures (1 of 2)
Reconciliation of GAAP to Non-GAAP Financial Measures (1 of 2) Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Ended March 31, 2024 2023 GAAP gross profit $ 19,626 $ 16,926 Shipping and handl
Slide 9: Reconciliation of GAAP to Non-GAAP Financial Measures (2 of 2)
Reconciliation of GAAP to Non-GAAP Financial Measures (2 of 2) Three Months Ended, June 2022 September 2022 December 2022 March 2023 June 2023 September 2023 December 2023 March 2024 GAAP gross profit $ 8,711 $ 10,944 $ 12,592 $ 16,926 $ 19,138 $ 17,783 $ 16,799 $ 19,626 Shipping and handling costs
Slide 10: „
„